Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA Approves CSL Behring’s Berinert
The FDA has approved CSL Behring’s Berinert for the treatment of acute abdominal attacks and facial swelling associated with hereditary angioedema (HAE). Berinert, a protein product derived from
The FDA has approved CSL Behring’s Berinert for the treatment of acute abdominal attacks and facial swelling associated with hereditary angioedema (HAE). Berinert, a protein product derived from
The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee has reviewed Fibrocell Science’s azfibrocel-T, an autologous cell therapy being investigated for the treatment of moderate-to-severe nasolabial fold wrinkles
Lid Hair Studios has completed its reverse merger with Shaanxi Jiali Pharmaceuticals (Shaanxi Jiali). Concurrent, the company has appointed the following Officers and Directors: Jun Xia as president,
Blue Marble Energy and Bionavitas have entered into a partnership in which Blue Marble Energy will produce biochemicals from microalgae supplied by Bionavitas. Based in Redmond, Washington, Bionavitas
Avanir Pharmaceuticals has released the results from the confirmatory double-blind phase III star trial evaluating two doses of the investigational drug Zenvia compared to placebo in the treatment
The Kansas Bioscience Authority (KBA) has increased the amount of venture capital available to innovative Kansas bioscience businesses, to lead the state’s economic recovery approving a commitment to
Biomet has reported an increase in net sales by 4% to $630.1m for the first quarter ended August 31,2009, compared to $607m for the same period prior year.
Intralytix has received a US Army phase I STTR contract, supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections. Shigella is a major gastrointestinal tract
Purdue Pharma is working with the FDA for the development of a new version its OxyContin pain medication. It has met with the Joint FDA Advisory Committee for
APP Pharmaceuticals, a wholly-owned subsidiary of Fresenius Kabi Pharmaceuticals (Kabi), has received approval from the FDA to market Sumatriptan Succinate Injection, USP, in two dosage strengths. Sumatriptan Succinate